Table 2.
Summary of 8-Week Response by Treatment
| Response | Arm 1 (erlotinib) | Arm 2 (erlotinib + MK-2206) | Arm 3 (MK-2206 + AZD6244) | Arm 4 (sorafenib) | Total | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| No. | % | No. | % | No. | % | No. | % | No. | % | |
| PR | 0 | 0 | 0 | 0 | 3 | 4 | 3 | 5 | 6 | 3 |
| SD | 6 | 32 | 18 | 50 | 34 | 49 | 25 | 41 | 83 | 45 |
| 8-week DCR (PR + SD) | 6 | 32 | 18 | 50 | 37 | 53 | 28 | 46 | 89 | 48 |
| PD | 13 | 68 | 18 | 50 | 33 | 47 | 33 | 54 | 97 | 52 |
| Not evaluable* | 3 | 6 | 5 | 0 | 14 | |||||
Abbreviations: DCR, disease control rate; PD, progressive disease; PR, partial response; SD, stable disease
*
Two patients were not evaluable because they did not complete treatment, one because the patient was retrospectively found to be noneligible because the tumor harbored an EGFR-sensitizing mutation that was not detected during screening.